CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 47 enrolled
Drug / intervention
Mitoquinol +1 moredrug
Likely dose
Mitoquinol 40 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04026711
NCT04026711Phase 1Completed
CompareCT.gov

MitoQ for the Treatment of Metabolic Dysfunction in Asthma

University of Vermont·interventional·Posted Jul 19, 2019·Updated Dec 11, 2025

In Brief

A Phase 1 clinical trial evaluating Mitoquinol and Placebo oral tablet for Asthma and Obesity. Completed, enrolled 47 participants across 2 sites.

Detailed Summary

A 14-week, randomized, placebo-controlled, double-masked clinical trial in 40 obese patients with poorly controlled asthma. The intervention is Mitoquinol (MitoQ) versus placebo. The primary aim of this pilot study is to determine if MitoQ improves airway reactivity in obese patients with asthma.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAsthma, Obesity
CountriesUnited States
CollaboratorsDuke University

Timeline

Phase 1CompletedFinished
2020202120222023202420252026
First PostedJul 19, 2019
Enrollment StartJan 1, 2020
Primary CompletionMar 31, 2024
TodayJul 2, 2026
Enrollment to primary: 4.3 yearsPosted 7.0 years ago

Interventions

Mitoquinoldrug

Mitoquinol (MitoQ) 40 mg per day for 12 weeks

Placebo oral tabletdrug

Placebo daily for 12 weeks